Issue Date: July 19, 2010
Wellcome Trust Invests in Kymab
Kymab, a Cambridge, England-based biopharmaceutical firm, has snagged $30 million from Wellcome Trust’s investment division in its first round of financing. Kymab was spun off from the labs of Allan Bradley, director emeritus of Wellcome Trust Sanger Institute. Kymab owns monoclonal antibody development technology that uses mice whose engineered chromosomes endow them with the B lymphocyte component of the human immune system. The company says its technology should enable a diverse array of highly selective, potent, and well-tolerated antibody-based drugs.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society